je.st
news
Tag: pharmaceutical
Endo Buys Par Pharmaceutical; Intel, Altera Relaunch Deal Talks
2015-05-19 13:41:58| Biotech - Topix.net
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 9+ You may proceed to the site by clicking here , however some pages might not work correctly.
Endo To Purchase Par Pharmaceutical
2015-05-19 10:32:25| Biotech - Topix.net
Endo , a specialty drug firm based in Ireland, will pay $8.1 billion in cash and stock to acquire the U.S.-based generic drug firm Par Pharmaceutical . The combined business will have about $4.2 billion in annual sales.
Tags: par
purchase
pharmaceutical
endo
High-Performance Clean Process Oven Fulfills Depyrogenation Standards Under New Compounding Pharmaceutical Requirements
2015-05-14 12:31:10| Industrial Newsroom - All News for Today
LAKEVILLE. Minn. As compounding pharmacists comply with tighter federal regulations enacted after the 2012 deadly fungal meningitis outbreak, a Florida pharmacist has discovered a clean process oven that is helping his compounding facility meet those higher depyrogenation safety standards. Pharmacist Vern Allen...
Tags: process
requirements
standards
clean
Market Report, "Pharmaceutical Packaging Market in North America 2015-2019", published
2015-05-08 22:18:38| Paper - Topix.net
Pharmaceutical packaging products have strong barrier properties, are meant to be portable, and are available in both unit dosage and multi-dose formats. International regulations regarding safe drug delivery are enforced by regulatory bodies on drug manufacturers, which in turn fuels adoption of sustainable packaging.
Tags: report
north
market
published
BIO addresses Pharmaceutical Cost Transparency Act.
2015-05-01 14:31:07| Industrial Newsroom - All News for Today
BIO President and CEO Jim Greenwood made statement regarding California State Assembly's burdensome legislation. "While the Assembly’s efforts to address health care costs for patients are well intended, the Pharmaceutical Cost Transparency Act of 2015 (AB 463) does nothing to improve patient access to medicines that have been put virtually out of reach by insurance company specialty tiers that have such high copays and co-insurance requirements that patients feel they no longer have insurance."
Sites : [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] next »